May. 26 at 3:01 PM
$IOVA I am loading up
$NYXH, FDA approved, good reimbursement, initial stage of commercialization, currently it’s totally under radar with stock price at 52 weeks low. Its revenue forecast for 2026 is about
$36-40M, sequential growth 25-30%,market cap
$120M. It is major and only competitor to
$INSP, with billion dollar TAM. The only risk is cash burn and needs to have capital raise. Can anyone here please do some DD to see if you think it’s a viable investment?